Filtered By:
Condition: Thrombosis
Drug: Angiomax

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 44 results found since Jan 2013.

Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study
The objective of this study was to examine the efficacy and safety of bivalirudin during percutaneous coronary intervention (PCI) in patients with CTO.METHODS: This trial used a retrospective cohort study design. Medical information from 736 patients with CTO who underwent PCI with bivalirudin or UFH at the First Affiliated Hospital of Zhengzhou University from July 2019 to September 2020 was extracted and analyzed. The primary end point was the 30-day incidence of net adverse clinical events (NACEs), and the secondary end point was the major adverse cardiovascular events (MACEs), which were related to safety and efficacy,...
Source: Clinical Therapeutics - April 3, 2021 Category: Drugs & Pharmacology Authors: Yanghui Zhang Yahao Zhang Chao Chang Shumei Yan Zheng Chen Lishuai Zhang Kui Chen Guizhi Liu Source Type: research

Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments
CONCLUSIONS: NETs were elevated in STEMI patients, increased by pPCI and decreased thereafter. One of the most specific NETs markers was associated with cardiovascular outcomes.PMID:35306431 | DOI:10.1016/j.thromres.2022.03.002
Source: Cell Research - March 20, 2022 Category: Cytology Authors: Maria Ferr é-Vallverdú Ana Mar ía Latorre Mar ía Paz Fuset Elena S ánchez Isabel Madrid Francisco Ten Juana Vall és Mar ía Teresa Santos Santiago Bonanad Antonio Moscard ó Source Type: research

Bivalirudin or Unfractionated Heparin for Anticoagulation in Pediatric Patients on Continuous Flow Ventricular Assist Device Support: Single-Center Retrospective Cohort Study
Conclusions: Use of bivalirudin for anticoagulation in patients on CF-VAD support was associated with lesser odds of hemorrhagic complications compared with use of UFH. Bivalirudin “washout” was successful in medical management of six of eight cases of possible pump thrombosis.
Source: Pediatric Critical Care Medicine - October 1, 2022 Category: Pediatrics Tags: Online Cardiac Intensive Care Source Type: research

Anticoagulation strategies in COVID-19 infected patients receiving ECMO support
CONCLUSION: In hospitalized patients with COVID-19-associated acute respiratory distress syndrome (ARDS) on VV ECMO support, the use of bivalirudin showed to be a viable anticoagulation alternative in terms of efficacy compared to UFH and resulted in a favorable safety profile with lower rates of bleeding and thrombotic events.PMID:37682210 | DOI:10.1051/ject/2023027
Source: Journal of Extra-Corporeal Technology - September 8, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Dayne Diaz Jenny Martinez Grant Bushman William R Wolowich Source Type: research